What WELL Health Technologies Holders Got Wrong Before The Slide - Simply Wall Street
This story deserves to be shared
Send it to someone who'd care, or post it on your networks.
If you had decided in October 2025 that the excitement around digitization and AI in Canadian healthcare felt too optimistic for WELL Health Technologies and chosen to skip the shares, the outcome might look different now. Holding WELL Health Technologies over the past year would have meant a 29.0% loss, including dividends. With upbeat analyst targets on record back then and strong recent headlines on clinic growth and guidance, which early assumptions about acquisitions, margins, or concentration in Canada would you have challenged most? On Simply Wall St, a Narrative is an investor's thesis written down: the reasoning, plus the numbers it rests on. Run those numbers and you get an estimated Fair Value. The move put WELL Health Technologies in the middle of this trade. Scan 5 healthcare AI stocks for other companies exposed to it. The Argument Investors Had To Settle On WELL Health Technologies The shares cost CA$5.6 at the start of the period, and you were weighing two very different stories about where WELL Health Technologies might go next. The bullish Narrative put Fair Value at CA$7.65.
This article is an excerpt. To read the full content, visit the original source. Simply Wall Street
Related articles
Continuous glucose monitors help type 2 diabetes patients spend 5 more hours a day in healthy blood sugar range - Medical Xpress
Continuous glucose monitors (CGMs) could transform diabetes management for millions of Americans with type 2 diabetes who don't take insulin, according to findings published in the New England Journal of Medicine. The clinical trial found that adults using CGMs spent approximately five additional hours each day within their target blood sugar range compared with those receiving routine care. Nearly twice as many CGM users also achieved an A1c level below 7%, a common treatment goal for people with diabetes.
Wearing headphones during surgery may reduce nausea and vomiting afterward - Medical Xpress
Patients who wore noise-canceling headphones during minimally invasive gynecological surgery were significantly less likely to experience postoperative nausea and vomiting (PONV), suggest findings from a randomized clinical trial presented at the Anesthesiology 2026 annual meeting.
Kefah Mokbel: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? - Oncodaily
“Beyond Detecting Cancer Recurrence: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? An exciting new study published in The Oncologist highlights the clinical potential of Signatera Genome, a whole-genome sequencing (WGS)-based, tumor-informed circulating tumor DNA (ctDNA) assay, not only for detecting molecular residual disease (MRD), but also for potentially informing adjuvant treatment decisions.
0 comments
No comments yet. Be the first to share your thoughts!